Informations sur le produit
PF-06263276 is a modulator that binds to the ATP binding site of the tyrosine kinase and inhibits its activity. It has been shown to be effective in treating inflammatory bowel disease in clinical studies. PF-06263276 is being developed as an alternative to baricitinib, which is currently undergoing clinical trials for treatment of rheumatoid arthritis. The mechanism of PF-06263276 has not been fully elucidated, but it has been hypothesized that it may work by preventing the activation of cells that are involved in inflammatory responses. This drug also prevents the synthesis of proinflammatory cytokines and chemokines and decreases the production of reactive oxygen species (ROS) from neutrophils.
Propriétés chimiques
Question d’ordre technique sur : 3D-WGC50262 PF-06263276
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages
